Blackstone and TPG Acquire Hologic Inc, Ending Nasdaq Listing

By Chris Stiles • Tuesday, April 07 16:18 • Permanent Link

Blackstone and TPG have completed their acquisition of Hologic in a deal valued at up to $79 per share, taking the women’s health company private and ending its Nasdaq listing.

Hologic shareholders are receiving $76 in cash per share plus a non-tradable contingent value right worth up to $3 per share, split into two payments of up to $1.50 each. The contingent payments are tied to Hologic’s breast health revenue targets in fiscal 2026 and 2027.

The transaction was announced on October 21, 2025, and approved by shareholders on February 5, 2026.

As part of the closing, José “Joe” E. Almeida has been named chief executive officer, effective immediately. Almeida most recently led Baxter International from 2016 to early 2025. Before that, he was chairman, president and CEO of Covidien until its 2015 sale to Medtronic.

Stephen MacMillan has retired after more than 12 years as Hologic’s chairman, president and CEO.

Hologic’s common stock has ceased trading and will be delisted from Nasdaq. Following these announcements, the company's shares moved 0.23%, and are now trading at a price of $75.69. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.